Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.4K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.4K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

86.3K
Overview
86.3K
Tissue Transplantation01:24

Tissue Transplantation

1.2K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD4+CD25+FOXP3+ Regulatory T Cells to Protect Against Graft Versus Host Disease.

Blood·2026
Same author

Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy.

Blood·2026
Same author

Selective Immune Silencing by Targeted TGF-β Agonists.

bioRxiv : the preprint server for biology·2026
Same author

Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.

Blood·2025
Same author

Regulatory T cell approaches for graft-versus-host disease prevention.

Current opinion in immunology·2025
Same author

Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy.

Blood advances·2025

Related Experiment Video

Updated: Mar 29, 2026

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.7K

Graft-versus-host disease versus graft-versus-leukemia.

Robert S Negrin1

  • 1Department of Medicine-Blood and Marrow Transplantation, Stanford University, Stanford, CA.

Hematology. American Society of Hematology. Education Program
|December 6, 2015
PubMed
Summary

Graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) are T cell-mediated outcomes of allogeneic hematopoietic cell transplantation. Researchers are exploring strategies to reduce GVHD while preserving GVL benefits for cancer patients.

More Related Videos

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.4K
Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

16.3K

Related Experiment Videos

Last Updated: Mar 29, 2026

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.7K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.4K
Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

16.3K

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Oncology

Background:

  • Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT), causing significant morbidity and mortality.
  • The graft-versus-leukemia (GVL) effect, also T cell-mediated, reduces relapse risk in hematological malignancies, presenting a therapeutic paradox.
  • Understanding the link between GVHD and GVL is crucial for optimizing HCT outcomes.

Purpose of the Study:

  • To review strategies aimed at mitigating GVHD while preserving or enhancing the beneficial GVL effect.
  • To explore approaches developed in preclinical models and translated to clinical settings.
  • To assess progress toward separating the detrimental GVHD from the therapeutic GVL response.

Main Methods:

  • Review of preclinical animal models and clinical studies.
  • Analysis of T cell-effector functions in the context of GVHD and GVL.
  • Evaluation of translational research strategies.

Main Results:

  • GVHD and GVL are both T cell-mediated phenomena, posing a challenge in transplantation.
  • Various strategies have been investigated to uncouple GVHD from GVL.
  • No single strategy has proven definitive, but progress is being made.

Conclusions:

  • Reducing GVHD while maintaining GVL remains a key goal in HCT.
  • Modern technologies and clinical translation are advancing strategies to achieve this balance.
  • Continued research is essential for improving HCT efficacy and patient survival.